ArticleBMC infectious diseases2026
Molecular and serodetection of hepatitis E virus among organ donors in the Czech Republic.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06457438 (Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionThe prevalence of hepatitis E virus (HEV) infection in the Czech Republic is high, and HEV represents a potential risk for immunosuppressed organ transplant recipients.
aimThe aim of this study was to investigate the prevalence of anti-HEV IgG and IgM antibodies and the presence of HEV RNA in organ donors in the Czech Republic in order to assess the potential risk of HEV transmission.
methodsIn this study, 73 organ donors sampled between 2022 and 2024 were examined. IgG and IgM antibodies against HEV were detected using an electrochemiluminescence immunoassay, and HEV RNA was assessed by molecular testing.
resultsA high prevalence of anti-HEV IgG antibodies (49.3%) and a low prevalence of anti-HEV IgM antibodies (2.7%) were observed. HEV RNA was not detected in any of the samples, indicating the absence of active infection. Higher donor age was significantly associated with anti-HEV IgG positivity (p = 0.046). The observed IgG prevalence was significantly higher than previously reported data from the Czech Republic based on samples collected in 2001.
conclusionDespite the absence of detectable HEV RNA, the high prevalence of anti-HEV IgG antibodies indicates substantial HEV exposure among organ donors. These findings may inform discussion on HEV screening strategies for organ donors, particularly in settings with high background prevalence, with PCR testing serving as a confirmatory tool following serological screening. However, the relatively limited sample size and the absence of recipient follow-up data represent important limitations of this study. CLINICAL TRIAL: ClinicalTrials.gov ID: NCT06457438. The study used residual serum material from organ donors, which would have otherwise been disposed of. No pressure was exerted on the donors or their family members to agree to organ donation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.